Distinctive regional asymmetry in dopaminergic and serotoninergic dysfunction in degenerative Parkinsonisms

Highly Conductive Peroxidase-like Ce-MoS2 Nanoflowers for the Simultaneous Electrochemical Detection of Dopamine and Epinephrine

The accurate and simultaneous detection of neurotransmitters, such as dopamine (DA) and epinephrine (EP), is of paramount importance in clinical diagnostic fields. Herein, we developed cerium-molybdenum disulfide nanoflowers (Ce-MoS2 NFs) using a simple one-pot hydrothermal method and demonstrated that they are highly conductive and exhibit significant peroxidase-mimicking activity, which was applied for the simultaneous electrochemical detection of DA and EP. Ce-MoS2 NFs showed a unique structure, comprising MoS2 NFs with divalent Ce ions. This structural design imparted a significantly enlarged surface area of 220.5 m2 g-1 with abundant active sites as well as enhanced redox properties, facilitating electron transfer and peroxidase-like catalytic action compared with bare MoS2 NFs without Ce incorporation. Based on these beneficial features, Ce-MoS2 NFs were incorporated onto a screen-printed electrode (Ce-MoS2 NFs/SPE), enabling the electrochemical detection of H2O2 based on their peroxidase-like activity. Ce-MoS2 NFs/SPE biosensors also showed distinct electrocatalytic oxidation characteristics for DA and EP, consequently yielding the highly selective, sensitive, and simultaneous detection of target DA and EP. Dynamic linear ranges for both DA and EP were determined to be 0.05~100 μM, with detection limits (S/N = 3) of 28 nM and 44 nM, respectively. This study shows the potential of hierarchically structured Ce-incorporated MoS2 NFs to enhance the detection performances of electrochemical biosensors, thus enabling extensive applications in healthcare, diagnostics, and environmental monitoring.

Molecular Imaging in Parkinsonian Disorders—What’s New and Hot?

Highlights

Abstract

Neurodegenerative parkinsonian disorders are characterized by a great diversity of clinical symptoms and underlying neuropathology, yet differential diagnosis during lifetime remains probabilistic. Molecular imaging is a powerful method to detect pathological changes in vivo on a cellular and molecular level with high specificity. Thereby, molecular imaging enables to investigate functional changes and pathological hallmarks in neurodegenerative disorders, thus allowing to better differentiate between different forms of degenerative parkinsonism, improve the accuracy of the clinical diagnosis and disentangle the pathophysiology of disease-related symptoms. The past decade led to significant progress in the field of molecular imaging, including the development of multiple new and promising radioactive tracers for single photon emission computed tomography (SPECT) and positron emission tomography (PET) as well as novel analytical methods. Here, we review the most recent advances in molecular imaging for the diagnosis, prognosis, and mechanistic understanding of parkinsonian disorders. First, advances in imaging of neurotransmission abnormalities, metabolism, synaptic density, inflammation, and pathological protein aggregation are reviewed, highlighting our renewed understanding regarding the multiplicity of neurodegenerative processes involved in parkinsonian disorders. Consequently, we review the role of molecular imaging in the context of disease-modifying interventions to follow neurodegeneration, ensure stratification, and target engagement in clinical trials.